$-0.23 EPS Expected for Mesoblast Limited (MESO)

August 13, 2018 - By Mary Gaskins

Mesoblast Limited (NASDAQ:MESO) Logo

Analysts expect Mesoblast Limited (NASDAQ:MESO) to report $-0.23 EPS on September, 4.They anticipate $0.09 EPS change or 28.13 % from last quarter’s $-0.32 EPS. After having $-0.22 EPS previously, Mesoblast Limited’s analysts see 4.55 % EPS growth. It closed at $6.3 lastly. It is down 33.14% since August 13, 2017 and is downtrending. It has underperformed by 45.71% the S&P500.

Mesoblast Limited develops cell-based medicines. The company has market cap of $642.85 million. The firm has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. It currently has negative earnings. The Company’s allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.

More recent Mesoblast Limited (NASDAQ:MESO) news were published by: Benzinga.com which released: “28 Stocks Moving In Tuesday’s Mid-Day Session” on July 17, 2018. Also Seekingalpha.com published the news titled: “Mesoblast inks partnership with Tasly Pharmaceutical Group” on July 17, 2018. Seekingalpha.com‘s news article titled: “Mesoblast Signs Deal In China For Stem Cell Heart Therapies” with publication date: July 18, 2018 was also an interesting one.

Mesoblast Limited (NASDAQ:MESO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.